发明名称 |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
摘要 |
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine. |
申请公布号 |
EP2899541(A1) |
申请公布日期 |
2015.07.29 |
申请号 |
EP20140165074 |
申请日期 |
2008.02.29 |
申请人 |
GENENTECH, INC.;F. HOFFMANN-LA ROCHE AG |
发明人 |
AMLER, LUKAS, C.;BIRKNER, MERRILL;LIN, CHIN-YU;MOECKS, JOACHIM;STRAUSS, ANDREAS |
分类号 |
G01N33/574;A61K39/395;C12Q1/68 |
主分类号 |
G01N33/574 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|